Biopharm company Alcobra (ADHD +4%) gets a lift from Aegis Capital this morning, who initiates coverage with a Buy rating and a price target of $30 per share. The stock has been something of a disappointment since its IPO debut in May. It priced at $8 and immediately broke below on its first day of trading, and still remains 11% underwater.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs